ClinicalTrials.gg
RecruitingNCT07249463CRYPTONITEUpdated Nov 10, 2026

Study Testing the Efficacy, Safety, and Tolerability of EDI048 in Cryptosporidium Infection Model in Healthy Adults

A Phase 2 interventional study of Cryptosporidium parvum oocysts (ABO809) and EDI048 in Cryptosporidiosis, sponsored by Novartis Pharmaceuticals. Recruiting at 2 sites in United States. Open to participants aged 18 Years to 50 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-10.

Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Started Dec 2025; still recruiting 11 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
80
Allocation
Randomized
Ages
18 Years to 50 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 17 studies in Cryptosporidiosis with a site in United States — 1 open to participants now, 1 under way, none of them phase 3. Cryptosporidiosis · United States.

Planned enrollment
Largest of 10
80 · median 36
Started
2025
the only one that year
Phase 2
3 of 17
1 open now
Registered
17th of 17
by date
Lead sponsor
2 of 17
Novartis Pharmaceuticals

Among the 17 studies in Cryptosporidiosis with a site in United States, this one has the largest planned enrollment of the 10 interventional ones that give a count, is the only one that started in 2025, is one of 3 in phase 2, and was the 17th registered.

Cryptosporidiosis

32 studies on the registry are indexed under Cryptosporidiosis; 6 are open to participants now.

Browse Cryptosporidiosis studies →

Open to participants now

1 of the 17 studies in Cryptosporidiosis with a site in United States is open now.

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 4 Cryptosporidiosis studies recruiting now, 1 sets no upper age limit and 3 stop at 75 or younger; 3 take children under 18; 2 take healthy volunteers.

This study: 18 Years to 50 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 17 studies in Cryptosporidiosis with a site in United States, or all of them as a file.
02

Study summary

This study has the purpose to demonstrate prospect of benefit of EDI048 on clinical signs and symptoms of cryptosporidiosis to facilitate trial in target population, pediatric patients.

This study aims to investigate the efficacy of a new chemical entity, EDI048, in a controlled human infection model of cryptosporidiosis induced by administration of ABO809 in healthy adults, who become symptomatic with disease thereby demonstrating a prospect of benefit for use of EDI048 in children afflicted with cryptosporidiosis.

Read the detailed description

This study is a Placebo-controlled, participant- and investigator-blinded multicenter trial in healthy adult volunteers who are administered Cryptosporidium parvum oocysts (ABO809) to develop diarrhea and symptoms consistent with cryptosporidiosis. After developing diarrhea, participants will be randomized 1:1 to treatment with EDI048 or placebo in parallel.

03

Conditions studied

  • Cryptosporidiosis

Browse trials for

Keywords

  • Cryptosporidiosis
  • Cryptosporidium
  • EDI048
  • ABO809
  • Controlled human infection model
  • CHIM
04

Who can participate

Ages eligible
18 Years to 50 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Signed must be obtained prior to participation in the study.
  • Ability to communicate well with the Investigator, and to understand and comply with the requirements of the study.
  • Male and female participants must be between 18 to 50 years of age and in good health as determined by medical history, physical examination, vital signs, , and laboratory tests at Screening and Baseline.
  • Demonstrate thorough understanding of cryptosporidiosis and measures to prevent secondary spread via education provided at screening.
  • Must have a (BMI) within the range of 18-32 kg/m2. BMI = Body weight (kg) / [Height (m)]2
  • Have not received ABO809 or EDI048 in prior clinical trials.

Exclusion criteria

Exclusion Criteria:

  • History of Cryptosporidium infection.
  • Current (based on screening laboratory tests) or history of infectious diarrhea associated with international travel in the last 12 months or C. difficile infection within 6 months prior to Screening.
  • Employment as a healthcare worker with direct patient care, in a daycare center (e.g., for children or the elderly), or direct food handler (individuals who work directly with food in commercial establishments).
  • Participants who share a home with any of the following:
  • a pregnant woman,
  • a person \<4 years old or >65 years old,
  • a person who is infirmed,
  • a person who is (for reasons including therapy, infection, cancer chemotherapy, or other chronic debilitating disease).
  • Residents of dormitories with shared bathrooms would also be excluded.
  • Any significant medical history including, but not limited to, conditions of the cardiac, pulmonary, gastrointestinal, renal, endocrine, reproductive, immune or other systems.
  • Use of drugs within 5 half-lives of the drug or its major metabolites or 30 days of enrollment (Day 1), whichever is longer.
  • Women of , defined as all women physiologically capable of becoming pregnant, unless they are using highly effective methods of throughout the trial; pregnant or nursing (lactating) women.
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
80 participants (estimated)

Study arms

  • Experimental
    EDI048

    Participants will receive ABO809 as a single oral dose. If participant is symptomatic, then he/she would be randomized to get EDI048 administered orally.

    Biological: Cryptosporidium parvum oocysts (ABO809) · Drug: EDI048

  • Placebo comparator
    Placebo

    Participants will receive ABO809 as a single oral dose. If participant is symptomatic, then he/she would be randomized to get placebo administered orally.

    Biological: Cryptosporidium parvum oocysts (ABO809) · Other: Placebo

Interventions

  • BiologicalCryptosporidium parvum oocysts (ABO809)

    ABO809 oral suspension, single dose

  • DrugEDI048

    EDI048 administered orally

  • OtherPlacebo

    Placebo administered orally

06

What researchers measure

Primary outcomes

  1. Average stool grade after the initiation of EDI048 or placebo treatment

    To determine the efficacy of EDI048 vs. placebo in healthy volunteers to reduce severity or resolve diarrhea.

    Time frame: Day 3, Day 4 and Day 5

Secondary outcomes

  1. Maximum stool grade after the initiation of EDI048 or placebo treatment

    To determine the efficacy of EDI048 vs. placebo in healthy volunteers to reduce severity or resolve diarrhea.

    Time frame: Day 3, Day 4 and Day 5

  2. Time to resolution of clinical diarrheal illness

    To evaluate the efficacy of EDI048 vs. placebo based on signs and symptoms associated with clinical diarrheal characteristics.

    Time frame: up to Day 35

  3. Number of participants with associated gastrointestinal symptoms

    To evaluate the efficacy of EDI048 vs. placebo based on signs and symptoms associated with clinical diarrheal characteristics.

    Time frame: up to Day 35

  4. Number of diarrhea episodes per participant

    To evaluate the efficacy of EDI048 vs. placebo based on signs and symptoms associated with clinical diarrheal characteristics.

    Time frame: up to Day 35

  5. Overall diarrheal stool weight

    To evaluate the efficacy of EDI048 vs. placebo based on signs and symptoms associated with clinical diarrheal characteristics.

    Time frame: up to Day 35

  6. Stool grade by stool grade category

    To evaluate the efficacy of EDI048 vs. placebo based on signs and symptoms associated with clinical diarrheal characteristics.

    Time frame: up to Day 35

  7. Number of participants with fecal shedding of Cryptosporidium parvum oocysts

    To evaluate the incidence of and time to resolution of Cryptosporidium infection in participants who received EDI048 vs. placebo.

    Time frame: up to Day 35

  8. Number of oocysts per gram per day (wet and dry weight) and the total number of oocyst per day measured by qPCR in fecal samples

    To quantify fecal shedding of oocysts in participants who received EDI048 vs. placebo and to assess time to resolution of infection.

    Time frame: up to Day 35

  9. PK parameter: Cmax

    To characterize PK of EDI048 and metabolite QPL621.

    Time frame: up to Day 5

  10. PK parameter: Tmax

    To characterize PK of EDI048 and metabolite QPL621.

    Time frame: up to Day 5

  11. PK parameter: AUC0-t

    To characterize PK of EDI048 and metabolite QPL621.

    Time frame: up to Day 5

  12. PK parameter: AUClast

    To characterize PK of EDI048 and metabolite QPL621.

    Time frame: up to Day 5

  13. PK parameter: AUCinf

    To characterize PK of EDI048 and metabolite QPL621.

    Time frame: up to Day 5

  14. PK parameter: T1/2

    To characterize PK of EDI048 and metabolite QPL621.

    Time frame: up to Day 5

  15. PK parameter: CI/F

    To characterize PK of EDI048 and metabolite QPL621.

    Time frame: up to Day 5

  16. PK parameter: V/F

    To characterize PK of EDI048 and metabolite QPL621.

    Time frame: up to Day 5

  17. Number of participants with adverse events of special interest (AESIs)

    To assess the safety and tolerability of EDI048 vs. placebo.

    Time frame: up to Day 35

07

Study locations

2 of 2 sites recruiting
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Dec 2025 (actual). Primary completion is estimated for Mar 2027, 15 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 18, 2025
First posted
Nov 25, 2025
StartActual
Dec 8, 2025
Primary completionEst.
Mar 23, 2027
CompletionEst.
Mar 23, 2027
Last update
Nov 10, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Minor edits
Nothing that changes what the study is or who can join. Edited: verification date
1 update, last Nov 10, 2026
Show all 1 update
  1. Nov 10, 2026
    Minor edits only
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT07249463
Responsible party
Sponsor
First posted
Nov 25, 2025
Start date
Dec 8, 2025
Primary completion
Mar 23, 2027 (estimated)
Completion
Mar 23, 2027 (estimated)
Last update
Nov 10, 2026

Study contacts

Novartis Pharmaceuticals
Contact
novartis.email@novartis.com
1-888-669-6682
Novartis Pharmaceuticals
Contact

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion